Testing XYA02 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer has come back or hasn't responded to standard treatments, and you've had at least one prior therapy (like chemotherapy or immunotherapy).
- You need to have measurable disease on scans and a life expectancy of at least 3 months.
- Your kidney, liver, and blood counts must be within certain limits, and you can't have had certain treatments recently (like chemotherapy or radiation within 28 days).
- You can't have untreated or symptomatic brain metastases, serious heart/lung problems, or active infections.
- You must be willing to provide a tumor sample from an earlier biopsy or get a new one if it's safe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
This study tests a new capsule, XS-02, for people with advanced solid tumors, especially ovarian cancer, that have stopped responding to standard treatments. The goal is to see if XS-02 is safe and helps shrink or control the cancer.
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called YL202 for people with advanced solid tumors (like lung, colon, or cervical cancer) who have already tried 1-2 standard treatments. It aims to see if YL202 can shrink tumors or slow their growth.
This trial is testing a new tablet called YY2201 for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help shrink or control the tumor.
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.